- BusinessMed spa: injectables, hormone therapy, facials, body and massage
- EngagementFractional CMO, since February 2026
- Figures throughQ3 2026, from the practice’s own booking and payment records
The Starting Point
A respected practice with years of history and a year that had gone the wrong way: card revenue in the third quarter of 2025 was down 10.5% on the year before, and one of its service lines had fallen away.
What The Work Looked Like
- Quarterly targets set by service line before the quarter began, and reviewed against at its close
- Marketing planned around the service lines each quarter’s targets named
- Lapsed clients, away more than a year, counted and won back as a number of their own
- A weekly numbers review, with the dashboard the whole team works from
The Results
4,296
Visits, busiest quarter on record
+31.5% on Q3 2025 and more than any quarter since records began in 2022. September was the busiest month on record.
136%
Of injectables target
$164,101 in Q3 2026 against a $121,000 target, the best quarter on record. September’s $65,276 was the best injectables month ever.
+11.5%
Card revenue, past target
$581,719 in Q3 2026, past its $575,000 target. The same quarter a year earlier had fallen 10.5%.
+40%
Lapsed clients won back
415 clients came back after more than a year away in Q2 and Q3 2026, against 297 a year earlier.
Across The Practice
+71%
Hormone therapy revenue
$75,035 from March to September 2026 against $43,760 a year earlier, with a record $34,454 in Q3.
$225,537
Best September on record
September 2026 sales: +14.5% on September 2025 and +31.2% on September 2024.
2.31
Visits per client, a record
Up from 1.87 a year earlier: clients coming back more often, the highest quarter on record.
+19%
Facials revenue
$143,688 from March to September 2026 against $120,719 a year earlier.
+15%
Gift card sales
$85,322 sold from March to September 2026 against $74,138 a year earlier. May’s $31,724 was the best May on record.
+6.5%
Sales growth, sped up
Over the first two full quarters of the engagement, against +0.6% over the two quarters before it.
How These Numbers Were Measured
Q3 2025 was a soft quarter to compare against; against Q3 2024, card revenue is level, because one service line fell from about $102k to $22k a quarter during 2025. Injectables and hormone therapy were growing before the engagement too, so the claims here are the records and the targets beaten, not the whole climb. A visit is a day with a service on a client’s account.